The Cambridge-based company embarked on Phase 3 of its study, dubbed COVE (Coronavirus Efficacy), in effort to test its prototype vaccine, and began administering doses to 30,000 Americans over the summer.
Russia's health minister Mikhail Murashko has informed that one in seven volunteers have complained of side effects, including weakness, muscle pain and fever after being injected with Sputnik V, Russia's vaccine against COVID-19.
Besides these, two vaccine candidates developed by Indian companies, Bharat Biotech and Zydus Cadila, are now undergoing combined phase-1 and phase-2 trials.
Public health officials have said that approving a vaccine for widespread use based on a small number of cases would not offer enough safety information to show how the vaccine would perform.
"This will ensure vaccine for Covid-19 is acquired quickly and at an affordable price once it has been proven to be safe and effective", the Ministry said adding that it will coordinate the agreement on behalf of the government.
The vaccine was said to use messenger RNA to prompt an immune response in the human body.
Robert Redfield, director of the US Centers for Disease Control and Prevention (CDC), testified before a Senate Appropriations Committee panel earlier this week and argued that he expects limited COVID-19 vaccinations to begin in November or December.
FILE - The Pfizer company logo is photographed at Pfizer Inc. headquarters, in New York, Dec. 4, 2017. These are: Gamaleya/Sputnik, Pfizer, AstraZeneca, Moderna and Sinovac. In an exclusive interview with India Today, GV Prasad said, "We have signed an MoU (Memorandum of Understanding) with the Russian Development Investment Fund (RDIF)".
U.S. President Donald Trump has long pushed for a COVID-19 vaccine to be ready before the country's November 3 elections.
The remaining 2.575 billion doses have either been bought by or promised to developing countries that include India, Bangladesh, China, Brazil, Indonesia and Mexico to name a few.
"We need a People's Vaccine, not a profit vaccine".
However, the European Union has publicly said it wants to boost the production capacity of vaccine makers and share any excess doses with poorer nations.
It is unclear when a vaccine will be available for children as major drugmakers have yet to include them in late-stage trials. And another 20 percent said they would refuse the vaccine.